Compare CCTG & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCTG | CALC |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 7.6M |
| IPO Year | 2022 | 2020 |
| Metric | CCTG | CALC |
|---|---|---|
| Price | $0.29 | $1.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 373.3K | 73.4K |
| Earning Date | 07-17-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.44 |
| 52 Week High | $5.64 | $72.00 |
| Indicator | CCTG | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 26.22 | 59.28 |
| Support Level | N/A | $1.00 |
| Resistance Level | $0.54 | $2.31 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 44.55 | 98.80 |
CCSC Technology International Holdings Ltd, through its direct wholly-owned subsidiaries, is principally engaged in the manufacturing and sale of interconnect products, including connectors, cables and wire harnesses. The company produces both original equipment manufacturer (OEM) and original design manufacturer (ODM) interconnect products for manufacturing companies that produce end products, as well as for electronic manufacturing services (EMS) companies. The majority of the company's revenue is derived from the sale of Cable and wire harnesses, and Connectors. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas, Asia, and Others.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.